Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Corporate Reputation of Pharma Companies, 2016-2017 from the Perspective of 98 Asian Patient Groups - Research and Markets

Research and Markets
Posted on: 14 Aug 17

The "The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 98 Asian Patient Groups" report has been added to Research and Markets' offering.

These Asian results are derived from a global review of pharma's corporate reputation (conducted November 2016 to early-February 2017).

The Asian results form the opinions of 98 patient groups: 42 came from Australasia; 11 from Central Asia; 27 from East Asia; 5 from South Asia; and 13 from South-East Asia.

16 pharma companies are included in this 2016 Asian analysis:

  • AbbVie
  • Astrazeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • GSK
  • Janssen
  • Merck & Co
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sandoz
  • Sanofi
  • Takeda

How pharma is assessed for corporate reputation

Industry-wide questions:

  • How the pharma industry's corporate reputation compares with that of other healthcare industries.
  • How the pharma industry's corporate reputation has changed over the past five years.
  • How good or bad the pharma industry is at various activities of relevance to patients and patient groups.

7 indicators show the corporate reputation of individual pharma companies:

  1. Patient centricity.
  2. Information for patients.
  3. Patient safety.
  4. Usefulness of products.
  5. Transparency.
  6. Integrity.
  7. Patient-group relationships (new for 2016).

INDUSTRY-WIDE FINDINGS

  • Asian patient groups were more positive about the pharma industry's corporate reputation than patient groups worldwide. In 2016, as many as 49.46% of Asian patient groups thought that the pharma industry had an Excellent or Good corporate reputation, compared with just 37.9% of patient groups from across the world. Asian patient groups ranked pharma 1st in 2016 among eight healthcare-industry sectors for having an
  • Excellent or Good corporate reputation. By contrast, patient groups from all geographic areas ranked pharma 5th in 2016.
  • Asian patient groups were more positive about many of the pharma industry's activities (with the exception of innovation).
  • How can pharma improve its corporate reputation? When respondent Asian patient groups were asked to single out the one activity most likely to help pharma improve its corporate reputation, 17% nominated fair pricing, 16% picked patient centricity, and 13% suggested having good relationships with patient groups.

THE RELATIONSHIPS BETWEEN PHARMA COMPANIES AND PATIENT GROUPS

  • The company with which Asian patient groups were most familiar was Pfizer (66% of respondent Asian patient groups were familiar with Pfizer). Followed by Novartis (at 60%).

INDIVIDUAL COMPANY FINDINGS

Results among patient groups familiar with the company

  • AbbVie ranked overall 1st for corporate reputation among Asian patient groups familiar with it. AbbVie also ranked 1st for three of the seven indicators of corporate reputation: patient centricity; transparency; and patient-group relations.
  • GSK ranked 1st for the provision of high-quality patient information.
  • Novo Nordisk ranked 1st for patient safety, for the provision of high-quality products, and for integrity (Novo Nordisk's favourable results were mostly driven by the respondent Asian haemophilia patient groups).

Results among patient groups that work with the company

  • GSK was positioned overall 1st for corporate reputation by its Asian patient-group partners. They also placed GSK 1st for five of the seven indicators of corporate reputation (the exceptions were patient centricity, and patient-group relations).
  • Eli Lilly was positioned 1st for patient centricity by its patient-group partners.
  • Novartis was positioned 1st for patient-group relations by its patient-group partners.

For more information about this report visit https://www.researchandmarkets.com/research/8mvknt/the_corporate

View source version on businesswire.com: http://www.businesswire.com/news/home/20170814005598/en/

Business Wire
www.businesswire.com

Last updated on: 14/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.